All In Biotech

Drug Trial Radar · NCT02290951

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)

Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

200

Actual

Start

Jan 9, 2015

Primary completion

Aug 21, 2025

Study completion Aug 21, 2025

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.

Conditions

  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia

Interventions

  • Odronextamab multiple dose levelsDrug

    Administered by intravenous (IV) infusion

  • Odronextamab multiple dose levelsDrug

    Administered by subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety/overall frequency of adverse events (AEs)Time frame: Up to 24 months
  2. Safety/dose limiting toxicities (DLTs)Time frame: Up to 28 days
  3. Antitumor activity as measured by the objective response rate (ORR)Time frame: Through study completion, an average of 24 months

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Orange, California

  • Stanford University

    Stanford, California

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • CHU Hôpital Lyon Sud

    Lyon, France

  • Centre Henri Becquerel

    Rouen, Haute-Normandie, France

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, France

  • Universitatsklinikum Wurzburg

    Würzburg, Bavaria, Germany

  • Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute

    Haifa, Israel

  • Lady Davis Carmel Medical Center

    Haifa, Israel

  • Meir Medical Center

    Kfar Saba, Central District, Israel

  • The Chaim Sheba Medical Center

    Tel-Hashomer, Central District, Israel

  • Hadassah Medical Center

    Jerusalem, Jerusalem, Israel

  • Assuta Ashdod University Hospital

    Ashdod, Southern District, Israel

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Royal Cornwall Hospitals NHS Trust

    Truro, Cornwall, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.